The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Open accessAbstract
BACKGROUND: Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye. Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity. METHODS: We conducted a prospective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity. Infants were randomly assigned to receive intravitreal bevacizumab (0.625 mg in 0.025 ml of solution) or conventional laser therapy, bilaterally. The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring retreatment before 54 weeks' postmenstrual age. RESULTS: We enrolled 150 infants (total sample of 300 eyes); 143 infants survived to 54 weeks' postmenstrual age, and the 7 infants who died were not included in the primary-outcome analyses. Retinopathy of prematurity recurred in 4 infants in the bevacizumab group (6 of 140 eyes [4%]) and 19 infants in the laser-therapy group (32 of 146 eyes [22%], P=0.002). A significant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II disease (P=0.27). CONCLUSIONS: Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina. This trial was too small to assess safety. (Funded by Research to Prevent Blindness and others; ClinicalTrials.gov number, NCT00622726.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Retinopathy of Prematurity Revisited
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.991 · Cited by 2,932
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1684 · Cited by 1,679
Screening Examination of Premature Infants for Retinopathy of Prematurity
Fierson, W. M., AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Chiang, M. F., Good, W., Phelps, D., Reynolds, J., Robbins, S. L., et al. (2018) · Pediatrics · doi:10.1542/peds.2018-3061 · Cited by 1,460
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1769 · Cited by 1,001
Gilbert, C. (2008) · Early Human Development · doi:10.1016/j.earlhumdev.2007.11.009 · Cited by 790
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results
(1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130517027 · Cited by 759
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Screening Examination of Premature Infants for Retinopathy of Prematurity
Ophthalmology, S. O., American Academy of Pediatrics, American Academy of Ophthalmology, & American Association for Pediatric Ophthalmology and Strabismus (2006) · Pediatrics · doi:10.1542/peds.2005-2749 · Cited by 444
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture
Smith, L. E. H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2584 · Cited by 194
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Screening Examination of Premature Infants for Retinopathy of Prematurity
Fierson, W. M., AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Chiang, M. F., Good, W., Phelps, D., Reynolds, J., Robbins, S. L., et al. (2018) · Pediatrics · doi:10.1542/peds.2018-3061 · Cited by 1,460
Hellström, A., Smith, L. E., & Dammann, O. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60178-6 · Cited by 1,304
Brown, J. M., Campbell, J. P., Beers, A., Chang, K., Ostmo, S., Chan, R. V. P., Dy, J., Erdogmus, D., Ioannidis, S., Kalpathy-Cramer, J., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1934 · Cited by 657
Mechanisms and Management of Retinopathy of Prematurity
Hartnett, M. E., & Penn, J. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1208129 · Cited by 637
Screening Examination of Premature Infants for Retinopathy of Prematurity
AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Fierson, W. M., Saunders, R. A., Good, W., Palmer, E. A., Phelps, D., Reynolds, J., et al. (2013) · Pediatrics · doi:10.1542/peds.2012-2996 · Cited by 588
Higashiyama, T., Muraki, S., & Ohji, M. (2017) · Case Reports in Ophthalmology · doi:10.1159/000461575 · Cited by 448
Stahl, A., Lepore, D., Fielder, A., Fleck, B., Reynolds, J. D., Chiang, M. F., Li, J., Liew, M., Maier, R., Zhu, Q., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31344-3 · Cited by 440
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
Retinal vasculature development in health and disease
Selvam, S., Kumar, T., & Fruttiger, M. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.001 · Cited by 353
Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity
Hartnett, M. E. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.050 · Cited by 351
Short- and Long-Term Outcomes for Extremely Preterm Infants
Patel, R. (2016) · American Journal of Perinatology · doi:10.1055/s-0035-1571202 · Cited by 341
Sato, T., Wada, K., Arahori, H., Kuno, N., Imoto, K., Iwahashi-Shima, C., & Kusaka, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.005 · Cited by 327
Geloneck, M. M., Chuang, A. Z., Clark, W. L., Hunt, M. G., Norman, A. A., Packwood, E. A., Tawansy, K. A., & Mintz-Hittner, H. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2772 · Cited by 327
Self-citationReactivation of Retinopathy of Prematurity After Bevacizumab Injection
Hu, J., Blair, M. P., Shapiro, M. J., Lichtenstein, S. J., Galasso, J. M., & Kapur, R. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.592 · Cited by 304
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
Genome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Bioactive lipids and pathological retinal angiogenesis
Elmasry, K., Ibrahim, A. S., Abdulmoneim, S., & Al‐Shabrawey, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14507 · Cited by 39
The genetics of retinopathy of prematurity: A model for neovascular retinal disease
Swan, R., Kim, S. J., Campbell, J. P., Chan, R. V. P., Sonmez, K., Taylor, K. D., Li, X., Chen, Y.-D. I., Rotter, J. I., Simmons, C., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.016 · Cited by 30
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Metadata
- Authors
- Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-17
- Volume
- 364
- Issue
- 7
- Pages
- 603-615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113170046
- Cited by
- 1,455
- References
- 25
- FWCI
- 59.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.